相关实验视频

Updated: Jun 17, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

RGI-2001 针对在异构HCT之后的急性移植病毒对宿主疾病的预防

Zachariah DeFilipp¹, Hannah K Choe², Yvonne A Efebera³

¹Massachusetts General Hospital, Boston, Massachusetts, United States.

|July 18, 2025

概括

RGI-2001是一种新疗法,通过减少急性移植对宿主疾病 (GVHD) 和改善生存率,在全源造血细胞移植中证明了安全性和有效性. 这种治疗激活免疫细胞,支持其在HCT接受者的潜力.

科学领域:

免疫学免疫学免疫学
血液学血液学血液学
在瘤学瘤学.

背景情况:

异构造血细胞移植 (HCT) 是血液恶性瘤的治愈疗法,但受到移植对宿主疾病 (GVHD) 的限制.
标准的GVHD预防可以损害有益的免疫复原,增加风险.
需要新的策略来缓解GVHD,同时促进HCT后有效的免疫恢复.

研究的目的:

评估RGI-2001的安全性和疗效,一个脂质体甘油脂,作为标准GVHD预防的辅助,在接受骨髓损伤性全源性HCT的患者中.
评估RGI-2001对急性GVHD发生率和整体存活率的影响.
调查RGI-2001的免疫调节作用,特别是其对不变的自然杀手T (NKT) 和调节性T (Treg) 细胞种群的影响.

主要方法:

一个开放的,单臂的,多中心的2b期试验,涉及49名参与者,他们接受了用于血液恶性瘤的骨髓剥离性异构HCT.
在RGI-2001中,每周给药量为100μg/kg,每周给药量为6剂,从HCT的0日开始,与标准的塔克罗利斯和甲状腺素治疗一起进行预防.
主要终点是HCT后第100天II-IV级急性GVHD的发病率. 二级终点包括安全性,耐受性和无GVHD生存率.

主要成果:

RGI-2001的耐受性很好,没有严重的输液反应. 与治疗相关的3级以上的不良事件发生在16名参与者中,最常见的是食欲下降,白血病,血小板减少和口腔炎.
据估计,II-IV级和III-IV级急性GVHD的概率分别为24.9%和4.1%.
与历史对照组相比,RGI-2001接受者显示显著改善了180日II-IV级急性GVHD无生存率 (70.8%与50.7%相比). 在HCT后观察到NKT和Treg细胞种群的增加.

结论:

RGI-2001是安全的,当与标准的GVHD预防结合时,可以很好地耐受,在骨髓缩性全源性HCT中.
RGI-2001显著降低了急性GVHD的发病率和改善了生存结果,证明了卓越的临床疗效.
使用像RGI-2001这样的药物向NKT和Treg细胞种群代表了一种有前途的策略,以增强HCT接受者的免疫复合和临床结果.

更多相关视频

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

相关概念视频

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

Kidney Transplant I: Introduction

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...